MRSS, median (range)
|
5.5 (3–10)
|
6 (5 − 7)
|
Disease duration from first non-Raynaud’s symptom, median (range) years
|
16 (4–40)
|
6 (2–28)
|
ANA primary pattern, N (%) patients
|
Homogenous
|
3 (30)
|
1 (20)
|
Speckled
|
1 (10)
|
1 (20)
|
Centromere
|
5 (50)
|
1 (20)
|
Nucleolar
|
0
|
1 (20)
|
SSc-specific antibodies
|
Scl-70
|
3 (30)
|
1 (10)
|
RNA pol III
|
0
|
0
|
Vasculopathy, N (%) patients
|
Digital ulcers
|
4 (40)
|
2 (40)
|
PAH
|
0
|
0
|
Renal crisis
|
0
|
0
|
Interstitial lung disease, N (%)
|
2 (20)
|
2 (40)
|
Inflammatory arthritis, N (%)
|
3 (30)
|
0
|
Vascular therapies, N (%) patients
|
ARB
|
8 (80)
|
2 (40)
|
Ca channel antagonist
|
2 (20)
|
2 (40)
|
Iloprost
|
3 (30)
|
1 (20)
|
PDE5 inhibitor
|
1 (10)
|
2 (40)
|
Immunosuppressive therapies, N (%) patients
|
PDN
|
2 (20)
|
2 (40)
|
MMF
|
2 (20)
|
1 (20)
|
MTX
|
2 (20)
|
0
|
AZA
|
1 (10)
|
0
|
HCQ
|
2 (20)
|
1 (20)
|